Time-dependent associations between iron and mortality in hemodialysis patients - PubMed (original) (raw)
. 2005 Oct;16(10):3070-80.
doi: 10.1681/ASN.2005040423. Epub 2005 Jul 20.
Affiliations
- PMID: 16033854
- DOI: 10.1681/ASN.2005040423
Time-dependent associations between iron and mortality in hemodialysis patients
Kamyar Kalantar-Zadeh et al. J Am Soc Nephrol. 2005 Oct.
Abstract
The independent association between the indices of iron stores or administered intravenous iron, both of which vary over time, and survival in patients who are on maintenance hemodialysis (MHD) is not clear. It was hypothesized that the observed associations between moderately high levels of three iron markers (serum ferritin, iron, and iron saturation ratio) or administered intravenous iron and all-cause and cardiovascular death is due to the time-varying confounding effect of malnutrition-inflammation-cachexia syndrome (MICS). Time-dependent Cox regression models were examined using prospectively collected data of the 2-yr (July 2001 to June 2003) historical cohort of 58,058 MHD patients from virtually all DaVita dialysis clinics in the United States. After time-dependent and multivariate adjustment for case mix, administered intravenous iron and erythropoietin doses, and available surrogates of MICS, serum ferritin levels between 200 and 1200 ng/ml (reference 100 to 199 ng/ml), serum iron levels between 60 and 120 microg/ml (reference 50 to 59 microg/ml), and iron saturation ratio between 30 and 50% (reference 45 to 50%) were associated with the lowest all-cause and cardiovascular death risks. Compared with those who did not receive intravenous iron, administered intravenous iron up to 400 mg/mo was associated with improved survival, whereas doses >400 mg/mo tended to be associated with higher death rates. The association between serum ferritin levels >800 ng/ml and mortality in MHD patients seems to be due mostly to the confounding effects of MICS. For ascertaining whether the observed associations between moderate doses of administered intravenous iron and improved survival are causal or due to selection bias by indication, clinical trials are warranted.
Comment in
- Intravenous iron: how much is too much?
Drüeke TB, Massy ZA. Drüeke TB, et al. J Am Soc Nephrol. 2005 Oct;16(10):2833-5. doi: 10.1681/ASN.2005080804. Epub 2005 Aug 31. J Am Soc Nephrol. 2005. PMID: 16135771 Review. No abstract available.
Similar articles
- Association between serum bicarbonate and death in hemodialysis patients: is it better to be acidotic or alkalotic?
Wu DY, Shinaberger CS, Regidor DL, McAllister CJ, Kopple JD, Kalantar-Zadeh K. Wu DY, et al. Clin J Am Soc Nephrol. 2006 Jan;1(1):70-8. doi: 10.2215/CJN.00010505. Epub 2005 Nov 23. Clin J Am Soc Nephrol. 2006. PMID: 17699193 - Longitudinal associations between dietary protein intake and survival in hemodialysis patients.
Shinaberger CS, Kilpatrick RD, Regidor DL, McAllister CJ, Greenland S, Kopple JD, Kalantar-Zadeh K. Shinaberger CS, et al. Am J Kidney Dis. 2006 Jul;48(1):37-49. doi: 10.1053/j.ajkd.2006.03.049. Am J Kidney Dis. 2006. PMID: 16797385 - Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population.
Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, Greenland S. Kalantar-Zadeh K, et al. Am J Kidney Dis. 2005 Sep;46(3):489-500. doi: 10.1053/j.ajkd.2005.05.020. Am J Kidney Dis. 2005. PMID: 16129211 - The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?
Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. Kalantar-Zadeh K, et al. Clin J Am Soc Nephrol. 2006 Sep;1 Suppl 1:S9-18. doi: 10.2215/CJN.01390406. Clin J Am Soc Nephrol. 2006. PMID: 17699375 Review. - Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: What is next?
Kalantar-Zadeh K. Kalantar-Zadeh K. Semin Dial. 2005 Sep-Oct;18(5):365-9. doi: 10.1111/j.1525-139X.2005.00074.x. Semin Dial. 2005. PMID: 16191172 Review.
Cited by
- Altered transcriptomic immune responses of maintenance hemodialysis patients to the COVID-19 mRNA vaccine.
Chang YS, Huang K, Lee JM, Vagts CL, Ascoli C, Amin MR, Ghassemi M, Lora CM, Edafetanure-Ibeh R, Huang Y, Cherian RA, Sarup N, Warpecha SR, Hwang S, Goel R, Turturice BA, Schott C, Hernandez M, Chen Y, Jorgensen J, Wang W, Rasic M, Novak RM, Finn PW, Perkins DL. Chang YS, et al. Elife. 2024 Apr 24;13:e83641. doi: 10.7554/eLife.83641. Elife. 2024. PMID: 38656290 Free PMC article. - Iron deficiency and supplementation in heart failure.
Lakhal-Littleton S, Cleland JGF. Lakhal-Littleton S, et al. Nat Rev Cardiol. 2024 Jul;21(7):463-486. doi: 10.1038/s41569-024-00988-1. Epub 2024 Feb 7. Nat Rev Cardiol. 2024. PMID: 38326440 Review. - Association of Estimated Total Body Iron with All-Cause Mortality in Japanese Hemodialysis Patients: The Miyazaki Dialysis Cohort Study.
Toida T, Sato Y, Komatsu H, Fujimoto S. Toida T, et al. Nutrients. 2023 Nov 3;15(21):4658. doi: 10.3390/nu15214658. Nutrients. 2023. PMID: 37960311 Free PMC article. - Elevated Ferritin Levels Associated with High Body Fat Mass Affect Mortality in Peritoneal Dialysis Patients.
Lee HS, Noh HM, An JN, Song YR, Kim SG, Kim JK. Lee HS, et al. Nutrients. 2023 Apr 29;15(9):2149. doi: 10.3390/nu15092149. Nutrients. 2023. PMID: 37432308 Free PMC article. - Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency.
Gómez-Ramírez S, Brilli E, Tarantino G, Girelli D, Muñoz M. Gómez-Ramírez S, et al. Pharmaceuticals (Basel). 2023 Jun 6;16(6):847. doi: 10.3390/ph16060847. Pharmaceuticals (Basel). 2023. PMID: 37375794 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical